Tag: Medexus Pharmaceuticals
-
![Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim]()
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…
-
![Multi-Company Wrap: Watching the watchlist so you don’t have to]()
Multi-Company Wrap: Watching the watchlist so you don’t have to
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on deaths door, some are skyrocketing, so we’ve decided to wrap them all up into one monthly wrap so you can keep track of everything at once.…
-
![Innovation and Growth: Canada’s Thriving Pharmaceutical Industry in the Global Market]()
Innovation and Growth: Canada’s Thriving Pharmaceutical Industry in the Global Market
Even though the COVID-19 pandemic posed challenges for healthcare and life sciences companies, Canada’s pharmaceutical industry continued to thrive, thanks to the government’s investments in pharma which buttressed the industry against the storm. Comprising a 2.1% share of the global pharmaceutical market, Canada now ranks as the 9th largest market worldwide. There’s no resting on…
-
![Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records]()
Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs that are already licensed in Western Europe and then bringing them to North America. A very smart business model which has seen Medexus carve…
-
![Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million]()
Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research and development, but instead bring over drugs that are already licensed in Western Europe to North America which sees them carve out a nice and profitable…
-
![Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector]()
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost. According to a recent study which tracked the success rates of clinical drug development through to FDA approval between 2006-2015, just 9.6% of the drug candidates…
-
![Medexus (MDP.T) resubmits Treosulfan NDA to FDA]()
Medexus (MDP.T) resubmits Treosulfan NDA to FDA
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted its New Drug Application (NDA) for treosulfan to the U.S. Food and Drug Administration. This submission was a response to the FDA request to submit information…
-
![First Glance with Jody Vance – Medexus Pharma (MDP.T)]()
First Glance with Jody Vance – Medexus Pharma (MDP.T)
Vancouver’s own Jody Vance speaks with Ken d’Entremont, Medexus Pharmaceuticals (MDP.V) CEO and director, to find out more about the company’s mandate of bringing established drugs approved in other countries to patients in Canada. Listen in! <div algn=”center:><iframe width=”803″ height=”452″ src=”https://www.youtube.com/embed/r4MwrGgePDo” title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture” allowfullscreen></iframe></div>
-
![Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder]()
Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however, before this turns into a sob story let me assure you that my mom is alive and well after kicking cancer’s ass. My mom was diagnosed…
-
![Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan]()
Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…
